title: [Heparin induced thrombocytopenia].
abstract: This article describes the pathogenesis, diagnostics, treatment and prevention of heparin induced thrombocytopenia (HIT). Although HIT is considered to be a hematological diagnosis, every physician who treats patients with heparin can encounter it in daily practice. It is even more probable that surgeons of any specialisation will meet with HIT patients. A section of them elude diagnostic detection. There are two forms of HIT - HIT I and HIT II. HIT I is caused by a direct pro-aggregation effect of heparin. It has no clinic significance. HIT II is an antidote mediated adverse reaction to heparin. Antidotes will generate only after the exposure to heparin. They are targeted against the platelet factor 4 and they act only at the presence of heparin. They may lead to the aggregation of thrombocytes in the vascular system (there is a decrease in thrombocyte count). This event can be accompanied by a development of venous or arterial thrombosis that can have a rapid and even fatal course. This fact clarifies the importance of HIT II diagnostics. Diagnosis of HIT II is based on recognizing of the typical decrease in thrombocyte count usually 1 day after heparin administration is initiated. Clinical manifestations are more likely in patients with already damaged endothelium. If thrombocyte count decrease is not connected with clinical manifestations, it is the so called isolated HIT II and in patients who display the signs of thrombosis, it is HIT II associated with thrombosis. The goal of this article is apart from implementing the recommendations of the 7th conference of the American Respiratory Society in real life also the exploration of the diagnostic and therapeutic limits (availability) in the Czech Republic.
authors.affiliation: Centrum pro trombózu a hemostázu pri Onkologickém centru J.G. Mendla, Nový Jicín. sona.kralova@pr-lab.cz
authors.forename: S
authors.initials: S
authors.lastname: Králová
authors.forename: D
authors.initials: D
authors.lastname: Klodová
authors.forename: J
authors.initials: J
authors.lastname: Gumulec
authors.forename: J
authors.initials: J
authors.lastname: Novotný
authors.forename: K
authors.initials: K
authors.lastname: Klaricová
authors.forename: M
authors.initials: M
authors.lastname: Wróbel
authors.forename: M
authors.initials: M
authors.lastname: Brejcha
authors.forename: E
authors.initials: E
authors.lastname: Sumná
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects*; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy
chemical_list: D000925:Anticoagulants; D006493:Heparin